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ess: richard.beasley@mSummary Introduction: The duration of bronchodilator action of the long-acting
beta agonist salmeterol when administered in the evening has not been investigated.
In this study we have investigated whether a single evening dose of salmeterol,
administered from the combination salmeterol/fluticasone (SFC) Accuhaler sig-
nificantly attenuates the circadian rhythm in airway tone over 24 h.
Methods: Eighteen subjects with mild to moderate asthma (mean FEV1 84%
predicted) participated in a double-blind, double dummy, placebo controlled, cross-
over study. Subjects inhaled, in random order, placebo, salbutamol (200 mg) or SFC
(50/100 mg) administered in the evening (2000 h) on three separate occasions. Lung
function measurements including FEV1, specific airways conductance (sGaw) and
maximum expiratory flow at 25–75% of vital capacity (MEF2575%) were assessed at
baseline, at 1 h and subsequently every 4 h post-dose for 24 h.
Results: Compared with placebo, SFC significantly improved the three measures
of airways function throughout the 24 h period, with a difference in FEV1 at 24 h of
0.24 l (0.00–0.47 l). SFC abolished the biphasic pattern of the circadian rhythm in
airway tone. In contrast, salbutamol had a significant bronchodilator action of 4–8 h,
depending on the lung function parameter measured.
Conclusion: The single evening administration of SFC via the Accuhaler resulted in
a duration of bronchodilation of at least 24 h, with the abolition of the accentuated
biphasic circadian variation in airway tone observed in asthma.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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While the efficacy of long-acting beta agonist drugs
are well established, their recommended use has
changed significantly since their introduction over
10 years ago. Initially long-acting beta agonists
were reserved for patients with severe asthma,
however recent international guidelines now re-
commend their use at Step 3, in moderately severe
patients not well controlled on low dose inhaled
corticosteroid therapy.1,2 The use of long-acting
beta agonists with inhaled corticosteroids from
combination inhaler devices ensures that long-
acting beta agonist drugs are not prescribed as
monotherapy and improves compliance with in-
haled corticosteroids.3
The incorporation of once daily dosing is another
important strategy to improve compliance, and is a
regime preferred by most patients.4,5 However,
before considering such a once daily regime with
combination long-acting beta agonist/inhaled cor-
ticosteroid therapy, it would be necessary to
investigate whether its use results in adequate
bronchodilation and anti-inflammatory effects.
While the efficacy of inhaled corticosteroids ad-
ministered once daily has been widely studied,6
this is not the case for the long-acting beta agonists
salmeterol or formoterol. To date there have been
few placebo-controlled studies of the bronchodi-
lator time course of action over a 24 h period,
following administration in the morning7–9 and only
a single study following evening administration.10
However, if long-acting beta agonists are to be used
once daily, it would seem preferable that they are
administered in the evening to ensure that the
maximum bronchodilator effect occurs during sleep
when the enhanced circadian rhythm results in the
greatest degree of bronchoconstriction. In this
study we have investigated whether a single dose
of the combination salmeterol/fluticasone (SFC) via
an Accuhaler would significantly attenuate the
circadian variation in airway tone and achieve
bronchodilation for at least 24 h.Methods
Subjects
Patients volunteering for this study were recruited
from newspaper advertising and from a database of
asthma volunteers. All subjects had to meet the
following criteria:
age 16–65 years; stable asthma; baseline forced
expiratory volume in 1 s (FEV1) X50% predicted;X15% reversibility in FEV1 (measured 15–30min
after 400 mg of inhaled salbutamol via MDI and
spacer) or a documented history of 15% reversi-
bility after inhaled beta agonist within three
months prior to the start of the study.
Exclusion criteria comprised a respiratory tract
infection or asthma exacerbation within 1 month of
entry into the study. Following enrolment, subjects
were withdrawn if their baseline FEV1 on one of the
study days was o50% predicted. The study was
approved by the Wellington Ethics Committee and
written informed consent was obtained from all the
subjects.
Study design
This was a double-blind, double-dummy, placebo-
controlled cross-over study. Subjects were ad-
mitted to Bowen Hospital for 24 h on three
occasions and slept overnight, being woken up for
lung function measurements. There was at least a
3-day interval between study days. Those patients
already taking a long-acting beta agonist abstained
from using this medication for 2 weeks prior to, and
for the duration of the study. During this 2 week
period and between treatment days, subjects
continued with the regular dose of their inhaled
corticosteroid therapy, and salbutamol aerosol as
required. On each of the study days patients took
their normal morning dose of inhaled corticosteroid
but withheld their evening dose. Smoking and
drinks containing caffeine were forbidden on study
days. Patients were instructed on current inhaler
technique.
After the assessment of lung function
(1915–2000 h), patients were instructed to inhale
placebo, salbutamol (2 100 mg), or SFC (1 50/
100 mg), in random order from blinded Accuhalers
(placebo and SFC) and metered-dose inhalers plus
spacer (placebo and salbutamol). Patients were
dosed at either 2000, 2010, 2020, 2030 or 2040 h.
Patients were dosed at the same time on each study
day (710min).
Lung function was measured at baseline, 1 h
post-dose, and then subsequently every 4 h post-
dose until the next evening (2100, 2400, 0400,
0800, 1200, 1600 and 2000 h). Measurements of
lung function included FEV1, airways resistance
(Raw), specific conductance (sGaw) and maximum
expiratory flow at 25–75% of forced vital capacity
(MEF2575%). FEV1 and MEF2575% were recorded at
the mouth using a pneumotacograph with electro-
nic integration (Jaeger, Wurzburg, Germany). The
highest value of three manoeuvres was retained as
per ATS guidelines. sGaw was calculated from
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Table 1 Patient characteristics.
Subject Sex Age Baseline ICS FEV1 (%
Duration of bronchodilator action of SFC 547airways resistance and thoracic gas volume, mea-
sured with a constant volume body plethysmograph
(Jaeger, Wurzburg, Germany).no. (years) mg/day (BDP
or equiv)
pred)
1 F 27 800 93
2 F 60 400 87
3 M 20 1000 110
4 F 46 1000 69
5 F 59 200 84
6 F 57 1000 83
7 F 56 500 81
8 M 18 200 92
9 F 47 400 70
10 M 60 1500 78
11 M 24 1000 80
12 F 21 0 80
13 F 30 400 92
14 F 44 200 90
15 F 26 500 90
16 F 51 2000 58
17 M 50 800 100
18 F 22 1000 73
Mean — 40 717 84
Range — 18–60 0–2000 58–110Data analysis
The primary outcome variable was FEV1, with sGaw
and MEF2575% representing the secondary outcome
variables. Two forms of mixed linear models were
used to model the cross-over with repeated
measures design.11,12 Firstly an analysis of co-
variance model using the baseline reading of the
particular outcome as a covariate, and accounting
for the repeated measures by specifying a varian-
ce–covariance matrix. A covariance structure that
resulted in a smaller value of ‘Akaikes information
criterion’ was used for each outcome variable. If
the time by treatment interaction term in the
analysis of covariance was significant, a set of
contrasts was estimated for the difference be-
tween each of the two active treatments and
placebo at 4, 8, 12, 16 and 24 h. The type 1 error
rate was controlled by choosing an appropriate
number of contrasts determined by the degrees of
freedom for the time by treatment interaction
term. Secondly a random coefficients model was
formed. The best fitting model specified cubic
polynomial functions for the salbutamol and place-
bo arms, to model the biphasic pattern of airflow,
and a linear function for the salmeterol and
fluticasone arm. SAS version 8.2 was used.Results
Eighteen mild to moderate asthmatics with a mean
(range) age of 40 (18–60) years and a mean (range)
FEV1 of 84% (58–110%) predicted were investigated
(Table 1). The mean pre-trial inhaled corticosteroid
dose was 717 mg/day (range 0–2000 mg/day) of
beclomethasone dipropionate (BDP) or equivalent.
One subject was an infrequent smoker of approxi-
mately two pack years who abstained for the
duration of the study. One subject who was with-
drawn from the study at Visit 1 as her baseline FEV1
was o50% was replaced by another subject. No
subjects required rescue medication on any of the
study days.
The baseline values for FEV1, sGaw and MEF2575
were not significantly different on the three study
days (P40:05). The mean (SD) for FEV1 was 2.62
(0.90) l before inhalation of placebo, 2.52 (0.90) l
before inhalation of salbutamol and 2.67 (0.92) l
before inhalation of SFC.Following the administration of placebo there
was a typical biphasic change in airway tone over
24 h with a nadir around 0400 h (8 h post dose) and a
peak at around 1200 h (16 h post dose) (Figs. 1–3).
The administration of SFC resulted in significant
bronchodilation throughout the 24 h period when
compared with placebo. This significantly greater
magnitude of bronchodilation was observed with all
three measures of lung function (Tables 2 and 3),
with a difference in FEV1 at 24 h of 0.24 l (95% CI
0.00–0.47 l). Following the administration of SFC
there was a gradual linear decline in lung function
throughout the 24 h period which contrasted with
the biphasic pattern observed with both placebo
and salbutamol (Figs. 1–3). Salbutamol had a
significant bronchodilator action of up to 4–8 h,
depending on the lung function parameter mea-
sured (Tables 2 and 3). The initial phase of the
biphasic pattern of lung function was higher
following salbutamol than placebo, however the
measurements were similar after the nadir at
0400 h (8 h post dose).
The figures show the estimated polynomial plots
together with the raw values for the outcome
variables. Table 4 shows the actual estimated
coefficients and their standard errors for the FEV1
measurement. Additional polynomial terms to the
SFC and removal of higher order terms for the other
treatments were not statistically significant and did
not improve the fit of the model.
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Figure 1 Plot of raw mean FEV1 values for each treatment arm: placebo (J), salbutamol (K), SFC (), and fitted
polynomial functions, placebo (____), salbutamol (??), SFC (_ _ _).
Figure 2 Plot of raw mean MEF values for each treatment arm: placebo (J), salbutamol (K), SFC (), and fitted
polynomial functions, placebo (____), salbutamol (??), SFC (_ _ _).
M. Masoli et al.548Discussion
This study has shown that the evening administra-
tion of SFC (50/100 mg via Accuhaler) results inbronchodilation which persists for at least 24 h. The
biphasic pattern of airway function which was
observed in the placebo and salbutamol groups
was abolished with the administration of SFC.
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Figure 3 Plot of raw mean sGaw values for each treatment arm: placebo (J), salbutamol (K), SFC (), and fitted
polynomial functions, placebo (____), salbutamol (??), SFC (_ _ _).
Table 2 Airway tone over 24 h.
Time Placebo Salbutamol SFC
FEV1 sGaw FEV1 SGaw FEV1 sGaw
Baseline 2.62 (0.9) 0.72 (0.25) 2.52 (0.9) 0.73 (0.32) 2.67 (0.92) 0.74 (0.32)
1 h 2.6 (0.9) 0.65 (0.36) 3.0 (1.0) 1.17 (0.30) 2.9 (1.0) 1.03 (0.36)
4 h 2.5 (0.8) 0.56 (0.15) 2.8 (1.0) 0.90 (0.24) 3.0 (1.1) 1.05 (0.34)
8 h 2.3 (0.7) 0.45 (0.12) 2.4 (0.7) 0.58 (0.14) 2.9 (1.1) 0.98 (0.29)
12 h 2.4 (0.8) 0.49 (0.16) 2.5 (0.8) 0.56 (0.15) 2.8 (1.0) 0.89 (0.36)
16 h 2.6 (0.9) 0.65 (0.19) 2.6 (0.9) 0.70 (0.21) 2.8 (1.0) 0.86 (0.26)
20 h 2.5 (0.9) 0.69 (0.26) 2.6 (0.9) 0.71 (0.22) 2.8 (1.0) 0.82 (0.24)
24 h 2.5 (0.9) 0.59 (0.20) 2.6 (0.9) 0.70 (0.19) 2.8 (1.0) 0.81 (0.26)
FEV1=forced expiratory volume in 1 s.
sGaw=specific airways conductance.
Mean (standard deviation).
Duration of bronchodilator action of SFC 549A number of methodological issues were con-
sidered in the design of this study relevant to the
interpretation of the findings. The first was the use
of both placebo and salbutamol arms in the cross-
over design. Placebo was used due to the marked
circadian variation in airway calibre that occurs in
asthma as a result of cyclical variations in the
inflammatory processes within the airway wall
combined with the circadian variation of vagal
activity and endogenous cortisol production.13–16
This was illustrated in our study in which patients
with apparently clinically stable asthma exhibited
considerable circadian variation in airway tonedespite regular treatment with inhaled corticoster-
oids, with a greater than 10% fall in FEV1 at the
nadir at 0400 h. The lack of a placebo arm to
determine the baseline circadian rhythm in lung
function has severely limited the interpretation of
some previous time course studies of long-acting
beta agonist drugs.17,18 The salbutamol arm was
included as a ‘‘control’’ bronchodilator treatment,
thereby ensuring that both the patient and the
investigators remained blinded to the active
medication.
Another issue was the use of different measures
of lung function to reflect different sites of the
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M. Masoli et al.550bronchodilator effect. Measurement of sGaw was
undertaken as this is a sensitive measure of large
airway function which is measured in the tidal
breathing range.19 Together with the measurement
of MEF2575% which was used to assess small airway
function, SGaw has the advantage of being effort
independent.19,20 The primary outcome variable
FEV1 was measured to obtain an integrated assess-
ment of both small and large airway function.20 A
similar bronchodilator duration of action was
observed following SFC with all three methods
used to assess airway calibre, suggesting that the
bronchodilator efficacy was present throughout
airways of varying size. The FEV1 also provided a
measure of lung function with which physicians are
clinically familiar. In this regard, we propose that
the magnitude of the 0.24 l improvement in FEV1
24 h after administration of SFC compared with
placebo is of clinical significance.
The decision to administer salmeterol from a
combination rather than a separate inhaler was
made due to the clinical preference for prescribing
long-acting beta agonist therapy in combination
with inhaled corticosteroids. This combination
regime ensures that salmeterol is not prescribed
as monotherapy and encourages compliance with
inhaled corticosteroids through its co-administra-
tion.3 However, administration of inhaled corticos-
teroids has been shown to result in a small acute
bronchodilator effect21,22 and it is therefore possi-
ble that a minor proportion of the bronchodilator
effect we observed with SFC in this study may have
resulted from the fluticasone component. In addi-
tion, there is evidence that inhaled corticosteroids
may enhance the bronchodilator effects of long-
acting beta agonists when given concurrently,23
particularly when administered from a combination
inhaler rather than with separate inhaler therapy.24
As a result, our results relate to salmeterol when
co-administered with fluticasone from a combina-
tion inhaler, and we are unable to determine the
duration of bronchodilator activity of salmeterol
alone when given in the evening. Likewise, we were
unable to determine whether fluticasone had any
bronchodilator activity when given alone in the
evening.
A salmeterol dose of 50 mg administered via an
Accuhaler was chosen as dose–response studies
have demonstrated that this can be considered to
be the optimal dose in terms of both efficacy and
side effects.7,8,18,25 The evening administration of
SFC was chosen because it seemed logical to
administer salmeterol prior to sleep, when the
enhanced circadian rhythm in asthma results in the
greatest degree of bronchoconstriction with the
associated risk of morbidity and mortality.26,27
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Table 4 FEV1—estimated coefficients for polynomial model.
Treatment Parameter Estimate (standard error) P
Placebo Intercept 2.7 (0.22) o0.0001
Time 0.10 (0.02) o0.0001
Time2 0.009 (0.002) o0.0001
Time3 0.0002 (0.00005) o0.0001
Salbutamol Intercept 3.2 (0.22) o0.0001
Time 0.16 (0.02) o0.0001
Time2 0.01 (0.002) o0.0001
Time3 0.0002 (0.00005) o0.0001
SFC Intercept 3.0 (0.22) o0.0001
Time 0.008 (0.002) o0.001
Duration of bronchodilator action of SFC 551Although it has yet to be determined whether
inhaled corticosteroids may have a greater effect
when given in the evening compared with the
morning, such an evening regime would seem
preferable for similar reasons in that the greatest
magnitude of airways inflammation is observed
overnight.28 The standard 100 mg dose of flutica-
sone administered in the SFC combination was
based on the recent evidence that 80–90% of the
maximum obtainable benefit with fluticasone is
achieved with 100 mg of fluticasone twice daily.29
Our findings differed to some degree from those
of the landmark study by Rabe et al.7 which
demonstrated that the bronchodilator effect of
salmeterol on FEV1 was not significantly different
from placebo beyond 12 h when administered in the
morning. Furthermore, in that study neither the
phase nor the amplitude of circadian variation over
24 h was different between salmeterol and place-
bo. In children, a 50 mg dose of salmeterol via a MDI
with spacer in the morning resulted in significant
bronchodilation at 12 h but not 24 h, although the
lack of airway measurements between these time
points prevented accurate determination of the
duration of bronchodilation.9
Following the administration of salmeterol at
1800 h, Fitzpatrick et al. reported that the noctur-
nal pattern of airway tone was not affected despite
significant bronchodilation, although the lack of
standardisation of the night-time peak flow record-
ings limits interpretation of this observation.21 In
contrast, Bootsma et al. reported that significant
bronchodilation occurred at 20 (but not 34) h after
a 50 mg dose of salmeterol delivered by MDI at
2200 h.10 The magnitude of the difference in FEV1
at 20 h with salmeterol compared with placebo was
10.4% of predicted values, similar to that observed
in our study. No correlation was found between the
bronchodilation and protection against provoked
bronchoconstriction provided by salmeterol at anytime point in this study, indicating that the
protection of salmeterol is not predominantly
caused by its bronchodilator activity. In the study
by Kemp et al.,8 both the 50 and 100 mg doses of
salmeterol administered in the morning resulted in
significant bronchodilation at 24 h, although the
lack of circadian variation in lung function follow-
ing placebo and the 415% bronchodilator response
to placebo limits the interpretation of this study.
Taken together these findings would suggest that a
long-acting beta agonist may have a greater
duration of bronchodilator action and provides
better protection against nocturnal bronchocon-
striction when administered in the evening com-
pared with morning dosing. However, this issue has
yet to be examined and will need to be investigated
in specific clinical trials.
In summary, the results of this study show that
administration of the combination SFC (50/100 mg)
Accuhaler in the evening provides significant
improvement in lung function over 24 h.References
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